16 hours Immunocore (IMCR) Upgraded to Buy: Here’s WhyZacks
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
X NYSE Nasdaq 100 Earnings Tech Science SEC U.S. Politics AI Business Energy Dow Jones Wall Street Dividend Investing Markets Crude Oil China Economy Wealth S&P 500 World Bitcoin (BTC) Real Estate NVIDIA (NVDA) Health Software Tesla (TSLA) 3M (MMM) Fed Insurance Gold Natural Gas Money Inflation Canada Entertainment Apple (AAPL) U.K. Options Pharmaceuticals Boeing (BA) Amazon (AMZN) Construction Retail Security Meta Platforms (META) Europe Microsoft (MSFT) Current JPMorgan (JPM) Hedge Funds Retirement Mining Jim Cramer Manufacturing Taxes Google Wells Fargo&Co (WFC) Goldman Sachs (GS) Donald Trump Truist Financial Corp (TFC) Netflix (NFLX) Finance Sports Elon Musk Aerospace Bank of America (BAC) Morgan Stanley (MS) Tax York Cars New York Silver Enterprise Japan Airlines Live REITs Israel Internet Economics Kamala Harris Interest Rates Costco (COST) Space Milton Mortgage Property Texas IPOs Florida Boston Warren Buffett Compound (COMP) Intel (INTC) BlackRock (BLK) ASML (ASML) AMD (AMD) WarMore +
